Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

[Unravel key factors to optimize combination of radiation and immunotherapy to improve bladder-organ preservation treatment in muscle-invasive bladder cancer / Déterminer les facteurs clés pour optimiser la combinaison de la radiothérapie et de l'immunothérapie dans le but d'améliorer la préservation de la vessie dans le cancer de la vessie invasif musculaire]

Original in French: Unravel key factors to optimize combination of radiation and immunotherapy to improve bladder-organ preservation treatment in muscle-invasive bladder cancer / Déterminer les facteurs clés pour optimiser la combinaison de la radiothérapie et de l'immunothérapie dans le but d'améliorer la préservation de la vessie dans le cancer de la vessie invasif musculaire

Funder: Cancer Research Society

Funding period
CAD 120 K
USD 91 K
Funding amount
Abstract
[Radical cystectomy remains the standard of care for invasive muscle-bladder cancer (MIBC). This surgery entails complete removal of the bladder and surrounding organs, leading to serious impact in quality of life (QoL) of patients and associated with a 5-year overall survival of only 50%. Radiation therapy (RT), which preserves the bladder, would be an appropriate treatment modality. Recently, promising results with immunotherapy in several cancers indicate that it may be an attractive strategy for MIBC. The New Approach to Innovative Cancer Treatment in Cancer (BC) is an unquestionably, positive impact in the survival and quality of life of MIBC patients. Radical cystectomy remains the "standard" therapy for cancer of the invasive muscle bladder. This surgery involves a complete elimination of the bladder and surrounding organs, having a significant impact on the quality of life of patients. Radiotherapy, which preserves the bladder, would be a more appropriate treatment modality if we could improve its effectiveness, because the lack of precision and the important toxicity remain problematic. Recently, promising results from immunotherapy for several types of cancer have suggested that the combination of immunotherapy and radiotherapy may be a winning strategy for overcoming resistance and improving the effectiveness of bladder cancer treatment. invasive muscle. This new approach could lead to major changes in the development of new bladder cancer treatment strategies, and have an undeniable positive impact on the survival and quality of life of patients with invasive muscle bladder cancer.]
Original in French
Radical cystectomy remains the standard of care for muscle-invasive bladder cancer (MIBC). This surgery entails complete removal of the bladder and surrounding organs, leading to serious impact in quality of life (QoL) of patients and associated with a 5-year overall survival of only 50%. Radiation therapy (RT), which preserves the bladder, would be an appropriate treatment modality if we could improve efficacy, as lack of local control and significant toxicity remain problematic. Recently, promising results with immunotherapy in several cancers indicate its combination with RT could be an attractive strategy to overcome resistance and to improve therapeutic efficacy in MIBC. The novel approach of the proposal herein can bring transformative changes in developing novel strategies in bladder cancer (BC) therapy as it has the potential to transfer from the bench to the patient, an unquestionably, positive impact in survival and quality of life of MIBC patients./La cystectomie radicale reste la thérapie "standard" pour le cancer de la vessie invasif musculaire. Cette chirurgie implique une élimination complète de la vessie et des organes environnants, ayant un impact important sur la qualité de vie des patients. La radiothérapie, qui préserve la vessie, serait une modalité de traitement plus appropriée si nous pouvions en améliorer l'efficacité, car le manque de précision et la toxicité importante restent problématiques. Récemment, des résultats prometteurs obtenus grâce à l'immunothérapie pour plusieurs types de cancer ont suggéré que la combinaison de l�immunothérapie et de la radiothérapie pourrait être une stratégie gagnante pour surmonter la résistance et améliorer l'efficacité du traitement du cancer de la vessie invasif musculaire. Cette nouvelle approche pourrait apporter des changements majeurs dans le développement de nouvelles stratégies de traitement du cancer de la vessie, et avoir un impact positif incontestable sur la survie et la qualité de vie des patients souffrant de cancer de la vessie invasif musculaire.
Similar projects All >
Sorted by: Start Date
Project list item
Investigating underlying molecular mechanisms of epigenetic therapies in muscle-invasive bladder cancer

Bladder Cancer Advocacy Network to Swathi Ramakrishnan

USD 1,700
2019 - 2019
Project list item
Understanding the Burden and Impact of Financial Toxicity in Bladder Cancer: A Mixed Methods Study of 2 Diverse Patient Populations

Bladder Cancer Advocacy Network to Sumeet Kaur Bhanvadia, Siamak Daneshmand, Reginald Tucker-Seeley

USD 50,000
2019 - 2020
Project list item
Quantifying Risk and Resilience (R2) among Patients with Bladder Cancer: A Novel Personalized, Comprehensive Risk Stratification Program

Bladder Cancer Advocacy Network to Sarah Psutka, Jonathan Wright, Daniel Lin, John Gore, Ryan O'Malley, Anne Browning, Florian Fintelmann

USD 50,000
2019 - 2020
Project list item
Recombinant CCL2 as a novel treatment strategy for bladder cancer

Bladder Cancer Advocacy Network to Neelam Mukherjee, Robert Scott Svatek

USD 50,000
2019 - 2020

System

Categories
  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Health Services

  • RCDC

    Cancer

  • RCDC

    Clinical Research

  • RCDC

    Urologic Diseases

  • HRCS HC

    Cancer

  • Health Research Areas

    Clinical

  • Broad Research Areas

    Clinical Medicine and Science